北京大学学报（医学版） ›› 2020, Vol. 52 ›› Issue (2): 204-206. doi: 10.19723/j.issn.1671-167X.2020.02.002
提高过继性T细胞免疫治疗临床疗效的新思考----肠道菌群与肿瘤免疫
任军,杨朵(
)
- 首都医科大学附属北京世纪坛医院肿瘤内科肿瘤实验室,肿瘤治疗性疫苗北京市重点实验室,北京 100038
中图分类号:
- R730.5
| [1] | Cruz-Ramos M, Garcia-Foncillas J . CAR-T cell and personalized medicine[J]. Adv Exp Med Biol, 2019(1168):131-145. |
| [2] | Gorabi AM, Hajighasemi S, Sathyapalan T , et al. Cell transfer-based immunotherapies in cancer: A review[J]. IUBMB Life, 72(4):790-800. |
| [3] | 钱其军, 吴孟超 . 肿瘤过继细胞治疗----老故事新演绎[J]. 中国肿瘤生物治疗杂志, 2011,18(1):1-6. |
| [4] | Wculek SK, Cueto FJ, Mujal AM , et al. Dendritic cells in cancer immunology and immunotherapy[J]. Nat Rev Immunol, 2020,20(1):7-24. |
| [5] | Jiang N, Qiao G, Wang X , et al. Dendritic cell/cytokine-induced killer cell immunotherapy combined with S-1 in patients with advanced pancrea-tic cancer: A prospective study[J]. Clin Cancer Res, 2017,23(17):5066-5073. |
| [6] | Wang X, Ren J, Zhang J , et al. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)[J]. Clin Transl Oncol, 2016,18(1):82-87. |
| [7] | Wang S, Wang X, Zhou X , et al.DC-CIK as a widely applicable cancer immunotherapy[J/OL].Expert Opin Biol Ther, ( 2020 -02-13). doi: 10.1080/14712598.2020.1728250. |
| [8] | Routy B, Gopalakrishnan V, Daillère R , et al. The gut microbiota influences anticancer immunosurveillance and general health[J]. Nat Rev Clin Oncol, 2018,15(6):382-396. |
| [9] | Goubet AG, Daillère R, Routy B , et al. The impact of the intestinal microbiota in therapeutic responses against cancer[J]. C R Biol, 2018,341(5):284-289. |
| [10] | Havel JJ, Chowell D, Chan TA . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J]. Nat Rev Cancer, 2019,19(3):133-150. |
| [11] | Sanmamed MF, Chen L . A paradigm shift in cancer immunotherapy: From enhancement to normalization[J]. Cell, 2018,175(2):313-326. |
| [12] | Li XV, Leonardi I, Iliev ID . Gut mycobiota in immunity and inflammatory disease[J]. Immunity, 2019,50(6):1365-1379. |
| [13] | Kamada N, Seo SU, Chen GY , et al. Role of the gut microbiota in immunity and inflammatory disease[J]. Nat Rev Immunol, 2013,13(5):321-335. |
| [14] | Round JL, Lee SM, Li J , et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota[J]. Science, 2011,332(6032):974-977. |
| [15] | Kim M, Galan C, Hill AA , et al. Critical role for the microbiota in CX3CR1 + intestinal mononuclear phagocyte regulation of intestinal T cell responses [J]. Immunity, 2018,49(1):151-163. |
| [16] | Fitzgibbon G, Mills KHG . The microbiota and immune-mediated diseases: Opportunities for therapeutic intervention[J]. Eur J Immunol, 2020,50(3):326-337. |
| [17] | Karin M, Jobin C, Balkwill F . Chemotherapy, immunity and microbiota: a new triumvirate?[J]. Nat Med, 2014,20(2):126-127. |
| [18] | Ganal SC, Sanos SL, Kallfass C , et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota[J]. Immunity, 2012,37(1):171-186. |
| [19] | Abid MB, Shah NN, Maatman TC , et al. Gut microbiome and CAR-T therapy[J]. Exp Hematol Oncol, 2019(8):31. |
| [20] | Paulos CM, Wrzesinski C, Kaiser A , et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 + T cells via TLR4 signaling [J]. J Clin Invest, 2007,117(8):2197-2204. |
| [21] | Dudley ME, Yang JC, Sherry R , et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens[J]. J Clin Oncol, 2008,26(32):5233-5239. |
| [22] | Uribe-Herranz M, Bittinger K, Rafail S , et al. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12[J]. JCI Insight, 2018,3(4):e94952. |
| [23] | Tanoue T, Morita S, Plichta DR , et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity[J]. Nature, 2019,565(7741):600-605. |
| [24] | Duell J, Dittrich M, Bedke T , et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL[J]. Leukemia, 2017,31(10):2181-2190. |
| [25] | Otoshi T, Nagano T, Tachihara M , et al. Possible biomarkers for cancer immunotherapy[J]. Cancers (Basel), 2019,11(7):935. |
| [1] | 季加孚, 韦静涛, 季科, 步召德. 胃癌诊疗的瓶颈与破局：迈向精准化与智能化融合的新纪元[J]. 北京大学学报（医学版）, 2026, 58(2): 231-238. |
| [2] | 高加勒, 张忠涛. 局部进展期直肠癌精准治疗现状与展望[J]. 北京大学学报（医学版）, 2026, 58(2): 247-250. |
| [3] | 王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 251-256. |
| [4] | 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报（医学版）, 2026, 58(2): 257-265. |
| [5] | 杜文, 章文博, 于尧, 刘硕, 苏惠裕, 胡耒豪, 唐祖南, 吴彬彰, 陈震, 李家琦, 王昊, 彭歆. 口腔颌面部肿瘤"数智化外科"诊疗流程探索与临床应用[J]. 北京大学学报（医学版）, 2026, 58(2): 278-284. |
| [6] | 王楠楠, 袁大晋, 朱昱冰, 丁磊. 结直肠癌根治术后肝转移风险多中心列线图预测模型的构建与验证[J]. 北京大学学报（医学版）, 2026, 58(2): 290-300. |
| [7] | 刘友东, 吕亚军, 陈杰, 臧明德, 潘宏达, 刘晓文, 陆俊, 刘凤林. 全腹腔镜保留贲门胃底胃次全切除术治疗中上部胃癌的疗效及安全性[J]. 北京大学学报（医学版）, 2026, 58(2): 301-306. |
| [8] | 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报（医学版）, 2026, 58(2): 399-404. |
| [9] | 李斌, 梁寒. 机器人胃癌根治术：研究进展与实践挑战[J]. 北京大学学报（医学版）, 2026, 58(2): 416-422. |
| [10] | 董海峰, 陈恒星, 张常华. 恶性肿瘤中蛋白质乳酸化修饰的研究进展[J]. 北京大学学报（医学版）, 2026, 58(2): 423-430. |
| [11] | 潘子晨, 陈凯, 侯钰坤, 杨博涵, 张继新, 马永蔌, 田孝东, 杨尹默. 胰腺腺鳞癌临床病理特征与分子机制研究进展[J]. 北京大学学报（医学版）, 2026, 58(2): 431-435. |
| [12] | 李宏杨, 黄涛, 王琳琳. 脂肪肌肉比率与卵巢良性肿瘤风险的关联性[J]. 北京大学学报（医学版）, 2026, 58(1): 169-174. |
| [13] | 高若凡, 马天宇, 王润楷, 殷雨辰, 李芮迪, 王丹丹, 夏斌. 细胞膜囊泡递送靶向肿瘤坏死因子-α的小干扰RNA对牙髓干细胞的抗炎作用[J]. 北京大学学报（医学版）, 2026, 58(1): 22-29. |
| [14] | 刘艳华, 陆敏, 赵旭阳, 张宽根, 武睿, 梅放, 戴志豪, 由江峰, 裴斐. 肿瘤转移抑制基因LASS2去磷酸化对液泡型ATP酶活性及前列腺癌侵袭性的影响[J]. 北京大学学报（医学版）, 2025, 57(6): 1113-1123. |
| [15] | 李浙民, 季加孚, 李国新, 李子禹, 步召德, 高翔宇, 董迪, 唐磊, 邢晓芳, 贾淑芹, 郭婷, 张连海, 陕飞, 季鑫, 王安强. 胃癌精准诊疗技术的创建与推广[J]. 北京大学学报（医学版）, 2025, 57(5): 864-867. |
|
||
